Showing results (261-270 of 295) with videos related to

Sort By:
Pageof 30
Annals of Surgical Oncology|January 7, 2014
Allelic imbalance at an 8q24 oncogenic SNP is involved in activating MYC in human colorectal cancerKeishi Sugimachi, Atsushi Niida, Ken Yamamoto, et al.
The Lancet. Gastroenterology & Hepatology|October 29, 2017
Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trialTetsuya Hamaguchi, Yasuhiro Shimada, Junki Mizusawa, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Survival outcomes following laparoscopic versus open D3 dissection for stage II or III colon cancer (JCOG0404): a phase 3, randomised controlled trialSeigo Kitano, Masafumi Inomata, Junki Mizusawa, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|June 6, 2013
Quality of gastric cancer care in designated cancer care hospitals in JapanTakahiro Higashi, Fumiaki Nakamura, Yasuhiro Shimada, et al.
Molecular Cancer Therapeutics|July 19, 2017
Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction CancerJosep Tabernero, Atsushi Ohtsu, Kei Muro, et al.
Clinical Colorectal Cancer|September 3, 2018
Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical TrialsTakayuki Yoshino, Kentaro Yamazaki, Eiji Shinozaki, et al.
The Lancet. Oncology|September 22, 2014
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialHansjochen Wilke, Kei Muro, Eric Van Cutsem, et al.
Langenbeck'S Archives of Surgery|February 25, 2022
A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT studyMasaru Matsumura, Kiyoshi Hasegawa, Masaru Oba, et al.
Journal of Gastric Cancer|July 7, 2017
Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient DataCharles S Fuchs, Kei Muro, Jiri Tomasek, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|October 30, 2015
Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancerKohei Shitara, Kei Muro, Yasuhiro Shimada, et al.
Pageof 30